Regen Biopharma Inc., of San Diego, said it has identified a series of compounds that interact with the company's newly identified immune checkpoint NR2F6. It is the first of a series of steps in developing small molecules, which the company plans to use as a basis for creating a checkpoint inhibitor pill.